RT Journal Article
SR Electronic
A1 Shuman, Jill
T1 Additional Results From SECURE
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 48
SP 8
OP 9
DO 10.1177/1559897715591482
UL http://mdc.sagepub.com/content/15/48/8.abstract
AB Data from the SECURE trial suggested that isavuconazole was not inferior to voriconazole when treating invasive fungal diseases. Data from 2 subsets of SECURE now show that patients taking isavuconazole are less likely to suffer from treatment-emergent adverse events and that the drug is both safe and effective for obese patients.